THE CORRELATIONS AMONG COMPONENTS OF METABOLIC SYNDROME PSA AND PROSTATE VOLUME IN BPH PATIENTS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study was to evaluate the associations among metabolic components, prostate specific antigen (PSA), and prostate volume (PV) in benign prostate hyperplasia (BPH) patients.Material & method: During the period from January 1, 2010 to August 31, 2013, 61 mens were diagnosed with BPH were enrolled. PV by transabdominal ultrasonography of the prostate, serum PSA, metabolic syndrome (MS) related parameters were investigated. MS was defined according to the modified National Cholesterol Education Program Third Adult Treatment Panel Guidelines. We evaluated the correlation between PSA, PV and MS components using Spearman’s test and Independent t test.Results: PV were not correlated with MS criteria (p=0.591) PSA total also were not correlated with MS criteria (p=0.305). PV were not correlated with each components MS; cholesterol total (p=0.593), trigliserid (p=0.479), HDL (p=0.702), LDL (p=0.512), blood glucose (p=0.317). PSA total were not correlated with each components MS; cholesterol total (p=0.255), trigliserid (p=0.543), HDL (p=0.446), LDL (p=0.615), blood glucose (p=0.987). Conclusion: There were no associations among metabolic syndrome criteria and each components, prostate volume and PSA total.
##plugins.themes.bootstrap3.article.details##
Prostate specific antigen total, prostate volume, metabolic syndrome, benign prostate hyperplasia
Epstein JL. Pathology of Prostatic Neoplasia. Dalam: wein AJ, Kovoussi LR, Novic AC, Partin AW, Peters CA, Ed. Campbell-Walsh Urology. Philadelphia: Saunders; 2007. p. 2874-82.
Ahmet G, Fatih R, Mursel D, Melviana D. The relationship between serum lipid levels and benign prostatic hyperplasia: original article. The New Journal of Medicine. 2010; 27: 148-50.
Sangyeoup L, Hong GM, Sang HC, Yun JK, Sang WO, Young JK, et al. Central obesity as a risk factor for prostatic hyperplasia; original article. J Obesity. 2006; 14: 172-9.
J. Kellogg, Jackyl B, Elizabeth BC. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJUI; 1001. p. 313-8.
Won TK, Seok J, Young DC, Young K, Sung KM, Yung HC, et al. Prostate size correlates with fasting blood glucose in non diabetic benign prostatic hyperplasia patients with normal testosteron levels: original article. J. Korean Med Sci. 2011; 26: 1214-8.
Yong JK, Yong JC, Sang CL. The association between metabolic syndrome and prostate specific antigen levels: original article. Int J Urol. 2008; 15: 905-9.
Abdollah F, Briganti A, Suardi N, Castiglione F. Metabolik syndrom and benign prostatic hyperplasia: evidence of potential relationship, hypothesized etiology, and prevention. Review article. Korean J Urol. 2011; 52: 507-16.
Rohrmann S, Smit E, Giovannucci E, Plat EA. Association between markers of the metabolik syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J of Obesity. 2005; 29: 310-6.
Norihiro H, Masato M, Toshihiro Y. The impact of hypertrigliceridemia on prostate cancer development in patient aged > 60 years. BJUI. 2011; 109: 515-9.